

EP17-A
Vol. 24 No. 34
Replaces EP17-P
Vol. 24 No. 10

Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline

This document provides guidance for determining the lower limit of detection of clinical laboratory methods, for verifying claimed limits, and for the proper use and interpretation of the limits.

A guideline for global application developed through the NCCLS consensus process.



NCCLS...

Global Consensus Standardization for Health Technologies

NCCLS is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the healthcare community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related healthcare issues. NCCLS is based on the principle that consensus is an effective and cost-effective way to improve patient testing and healthcare services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, NCCLS provides an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

PUBLICATIONS

An NCCLS document is published as a standard, guideline, or committee report.

Standard A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

Guideline A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

Report A document that has not been subjected to consensus review and is released by the Board of Directors.

CONSENSUS PROCESS

The NCCLS voluntary consensus process is a protocol establishing formal criteria for:

- the authorization of a project
- the development and open review of documents
- the revision of documents in response to comments by users
- the acceptance of a document as a consensus standard or guideline.

Most NCCLS documents are subject to two levels of consensus—"proposed" and "approved." Depending on the need for field evaluation or data collection, documents may also be made available for review at an intermediate consensus level.

Proposed An NCCLS consensus document undergoes the first stage of review by the healthcare community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

Approved An approved standard or guideline has achieved consensus within the healthcare community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (i.e., that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

NCCLS standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following NCCLS's established consensus procedures. Provisions in NCCLS standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the NCCLS committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are responded to by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any NCCLS document. Address comments to the NCCLS Executive Offices, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

VOLUNTEER PARTICIPATION

Healthcare professionals in all specialties are urged to volunteer for participation in NCCLS projects. Please contact the NCCLS Executive Offices for additional information on committee participation.

EP17-A
ISBN 1-56238-551-8
ISSN 0273-3099

Volume 24 Number 34

Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline

Daniel W. Tholen, M.S.
Kristian Linnet, M.D., Ph.D.
Marina Kondratovich, Ph.D.
David A. Armbruster, Ph.D., DABCC, FACB
Patricia E. Garrett, Ph.D.
Robert L. Jones, Ph.D.
Martin H. Kroll, M.D.
Rudolf M. Lequin, Ph.D.
Thomas J. Pankratz, Ph.D.
G.A. Scassellati, Ph.D.
Heinz Schimmel, Ph.D.
Jane Tsai, Ph.D.

Abstract

NCCLS document EP17-A—*Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline* provides protocols for determining the lower limit of detection of clinical laboratory methods, for verifying claimed limits, and for the proper use and interpretation of these limits. This document also provides guidance for determining lower limits of quantitation based on a laboratory's goals for performance at low-levels. This applies to all quantitative procedures, even if the reported result is qualitative. EP17-A is intended for use by clinical laboratories and by manufacturers of *in vitro* diagnostic tests.

NCCLS. *Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline*. NCCLS document EP17-A (ISBN 1-56238-551-8). NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.

THE NCCLS consensus process, which is the mechanism for moving a document through two or more levels of review by the healthcare community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of NCCLS documents. Current editions are listed in the *NCCLS Catalog*, which is distributed to member organizations, and to nonmembers on request. If your organization is not a member and would like to become one, and to request a copy of the *NCCLS Catalog*, contact the NCCLS Executive Offices. Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: exoffice@nccls.org; Website: www.nccls.org



This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system, transmitted, or made available in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without prior written permission from NCCLS, except as stated below.

NCCLS hereby grants permission to reproduce limited portions of this publication for use in laboratory procedure manuals at a single site, for interlibrary loan, or for use in educational programs provided that multiple copies of such reproduction shall include the following notice, be distributed without charge, and, in no event, contain more than 20% of the document's text.

Reproduced with permission, from NCCLS publication EP17-A—*Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline* (ISBN 1-56238-551-8). Copies of the current edition may be obtained from NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Permission to reproduce or otherwise use the text of this document to an extent that exceeds the exemptions granted here or under the Copyright Law must be obtained from NCCLS by written request. To request such permission, address inquiries to the Executive Vice President, NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania, 19087-1898, USA.

Copyright ©2004. The National Committee for Clinical Laboratory Standards.

Suggested Citation

(NCCLS. *Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline*. NCCLS document EP17-A [ISBN 1-56238-551-8]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.)

Proposed Guideline

March 2004

Approved Guideline

October 2004

ISBN 1-56238-551-8

ISSN 0273-3099

Committee Membership

Area Committee on Evaluation Protocols

Jan S. Krouwer, Ph.D.
Chairholder
Krouwer Consulting
Sherborn, Massachusetts

Luann Ochs, M.S.
Vice-Chairholder
Roche Diagnostics Corporation
Indianapolis, Indiana

Anders Kallner, M.D., Ph.D.
 Karolinska Hospital
 Stockholm, Sweden

Martin H. Kroll, M.D.
 Dallas VA Medical Center
 Dallas, Texas

Jacob (Jack) B. Levine, M.B.A.
 Bayer Corporation
 Tarrytown, New York

Kristian Linnet, M.D., Ph.D.
 Psychiatric University Hospital
 Risskov, Denmark

Kristen L. Meier, Ph.D.
 FDA Center for Devices and
 Radiologic Health
 Rockville, Maryland

Max Robinowitz, M.D.
 FDA Center for Devices and
 Radiologic Health
 Rockville, Maryland

Daniel W. Tholen, M.S.
 Dan Tholen Statistical Consulting
 Traverse City, Michigan

Advisors

David A. Armbruster, Ph.D.,
 DABCC, FACB
 Abbott Laboratories
 Abbott Park, Illinois

R. Neill Carey, Ph.D.
 Peninsula Regional Medical Center
 Salisbury, Maryland

Carl C. Garber, Ph.D., FACB
 Quest Diagnostics, Incorporated
 Lyndhurst, New Jersey

Patricia E. Garrett, Ph.D.
 Boston Biomedica, Inc.
 West Bridgewater, Massachusetts

Donald M. Powers, Ph.D.
 Powers Consulting Services
 Pittsford, New York

Gian Alfredo Scasselatti, Ph.D.
 Consultant, Ente Nazionale Italiano
 Di Unificazione
 Turin, Italy

Jack Zakowski, Ph.D., FACB
 Beckman Coulter, Inc.
 Brea, California

Subcommittee on Limits of Detection

Daniel W. Tholen, M.S.
Chairholder
Dan Tholen Statistical Consulting
Traverse City, Michigan

Patricia E. Garrett, Ph.D.
 Boston Biomedica, Inc.
 West Bridgewater, Massachusetts

Robert L. Jones, Ph.D.
 Centers for Disease Control and
 Prevention
 Atlanta, Georgia

Marina Kondratovich, Ph.D.
 FDA Center for Devices and
 Radiologic Health
 Rockville, Maryland

Martin H. Kroll, M.D.
 Dallas VA Medical Center
 Dallas, Texas

Kristian Linnet, M.D., Ph.D.
 Psychiatric University Hospital
 Risskov, Denmark

Thomas J. Pankratz, Ph.D.
 Dade Behring Inc. - Glasgow
 Newark, Delaware

Heinz Schimmel, Ph.D.,
 (IFCC liaison)
 IRMM
 Retieseweg, Belgium

Staff

Lois M. Schmidt, D.A.
Staff Liaison
 NCCLS
 Wayne, Pennsylvania

Patrice E. Polgar
Project Manager
 NCCLS
 Wayne, Pennsylvania

Donna M. Wilhelm
Editor
 NCCLS
 Wayne, Pennsylvania

Melissa A. Lewis
Assistant Editor
 NCCLS
 Wayne, Pennsylvania

The NCCLS Area Committee on Evaluation Protocols and its Subcommittee on Limits of Detection gratefully acknowledge the valuable contributions of the following authors of the guideline:

David A. Armbruster, Ph.D., DABCC, FACB
 Abbott Laboratories
 Abbott Park, Illinois

Rudolf M. Lequin, Ph.D.
 Diagnostics Consultancy
 Eindhoven, The Netherlands

Gian Alfredo Scasselatti, Ph.D.
 Consultant, Ente Nazionale Italiano Di Unificazione
 Turin, Italy

Jane Tsai, Ph.D.
 Roche Diagnostics Corp.
 Indianapolis, Indiana

Contents

Abstract	i
Committee Membership	iii
Foreword	vii
1 Scope	1
2 Introduction	1
2.1 Path of Development and Use	2
2.2 Common Practices	2
2.3 Terminology	3
2.4 Discussion of Limits of Detection and the Tie to Qualitative Tests	4
3 Definitions	5
4 Procedures for Determining and Verifying the Limit of Detection (LoD) for a Measurement Procedure	7
4.1 Overview	7
4.2 Study Design	10
4.3 Procedure to Determine and Verify the LoB and LoD	11
5 Limit of Quantitation (LoQ)	17
5.1 Establishing the Limit of Quantitation	18
5.2 Verifying a Claimed LoQ	18
6 Reporting Results	23
6.1 Reporting Intervals for Quantitative Results	23
6.2 Example of a Claim in Labeling	25
References	26
Appendix A. Standard Error of LoD and Estimation of Sample Size	27
Appendix B. Estimation of SDs	28
Appendix C. Example	29
Summary of Delegate Comments and Subcommittee Responses	36
The Quality System Approach	38
Related NCCLS Publications	39

Foreword

Laboratory methods have many performance characteristics that must be understood and assessed for their appropriate use. The performance characteristics for any method describe the method's capability to reliably measure the amount of an analyte in a subject's sample (although for some analytes, reliable detection is sufficient). Two such critical performance characteristics are defined at the lower end of the measurement scale. The first is the smallest amount that the method can reliably detect to determine presence or absence of an analyte. This is the limit of detection (LoD). The second characteristic is the smallest amount the method can reliably measure quantitatively. This is the limit of quantitation (LoQ).

The limits of detection and quantitation are critical because detecting extremely small amounts of an analyte can be necessary to define disease states, screen for disease, identify significant exposure, or to reveal the presence or absence of toxins, pollutants, carcinogens, contaminants, infectious agents, and illicit drugs. Some of these applications may effectively use the examination method as a qualitative or semiquantitative (ordinal scale) procedure. Although the discrimination point, or cutoff value, for a qualitative method is rarely designated by the developer to be equivalent to the lowest detectable amounts of the analyte, knowledge of the limit of detection informs the choice of a cutoff, so the procedures in this document should be applicable.

The LoD and LoQ are also important in laboratory examinations for tumor markers, hormones, agents of infectious diseases, therapeutic drugs, and other tests where low values separate subjects into different disease or exposure categories. Because of the statistical sophistication of these protocols, it is expected that this document will be used primarily by manufacturers and clinical laboratory supervisors.

A Note on Terminology

NCCLS, as a global leader in standardization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. NCCLS recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in NCCLS, ISO, and CEN documents; and that legally required use of terms, regional usage, and different consensus timelines are all obstacles to harmonization. In light of this, NCCLS recognizes that harmonization of terms facilitates the global application of standards and deserves immediate attention. Implementation of this policy must be an evolutionary and educational process that begins with new projects and revisions of existing documents.

The Subcommittee on Limits of Detection has made every effort to use globally accepted terms wherever possible. These are described in Sections 2.3.1 and 2.3.2 which discuss some commonly used terms that are not employed in this document, and in Section 3. Users are encouraged to comment on the choices made by the subcommittee, in the hope of eventually reaching full international harmonization of these terms and concepts.

Key Words

Limit of blank, limit of detection, limit of quantitation, nonparametric statistics

Acknowledgement

This guideline was prepared by NCCLS, as part of a cooperative effort with IFCC to work toward the advancement and dissemination of laboratory standards on a worldwide basis. NCCLS gratefully acknowledges the participation of IFCC in this project.

Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline

1 Scope

NCCLS document EP17 specifies recommendations for determining the lower limit of detection of clinical laboratory methods, for verifying claimed limits, and for the proper use and interpretation of the limits. It also provides guidance for determining lower limits of quantitation based on a laboratory's goals for performance at low-levels. EP17 may be applied to all measurement procedures (even if the reported result is qualitative), most notably those for which the medical decision level is low (i.e., approaching zero).

The intended users of this guideline are clinical laboratory supervisors and manufacturers of *in vitro* diagnostic tests.

2 Introduction

There have been a great number of procedures proposed for establishing the lower limits of detection and quantitation (LoD and LoQ) in laboratory measurement procedures. This document does not intend to review them all, nor does it attempt to find agreement among them. The needs of the clinical laboratory are unique in that the recommended procedure must apply to analytical devices as they are used in the laboratory setting. Usually, this means using the device as it is, often as set up and maintained by a manufacturer or its representatives.

The most commonly recommended statistical protocols for LoD and LoQ, including the ISO protocol 11843, Parts 1 to 4,¹⁻⁴ assume that the raw instrument output at low levels can result in negative concentrations. These protocols also assume that the signals for blank samples are normally distributed around some low average value (usually zero). However, many common clinical laboratory instruments report analyte levels in positive numbers only, and basic instrument analytical signals are not retrievable, so the preferred parametric models are not appropriate.

This protocol is intended for use with methods that report in mass or concentration units, and, in particular, in which there is clinical need or interest in very low concentrations (approaching zero). EP17 is intended for all methods, but it was designed specifically for use with methods that report "zero" or positive values only. Manufacturers or developers of methods who have access to the basic instrument response should consider use of ISO 11843-1¹ and either 11843-2² or 11843-3,³ depending on whether or not linear calibration data are available; these documents describe the internationally recognized procedures for determining the LoD. Usually, the expected limits of detection for the EP17 protocol are the same as for the ISO model, but the ISO procedure should return values with lower uncertainty. However, it is important to remember that the use of the parametric ISO procedures requires the validity of the assumptions of normality (Gaussian) at all tested levels, including the blank material.

Proper use of the ISO protocol will also require statistical sophistication that is often beyond the capabilities of most laboratories. The EP17 protocol is intended to be applied and understood without straining the resources available to most clinical laboratories. The procedures are based on the concepts used in conventional LoD procedures, but are practical for use with common clinical laboratory devices.

This protocol requires knowledge of the true (or accepted) levels of the measurand in samples being tested. There is little utility in estimates of precision around an unknown value. It is also important to recognize that modern electronic instruments do not possess continuous functions relating sensor and voltage or current output. The random error measured in the region of a blank may be truly random, but it